Interaction of morphine, fentanyl, sufentanil, affientanil, and loperamide with the efflux drug transporter p-glycoprotein

被引:179
作者
Wandel, C
Kim, R
Wood, M
Wood, A
机构
[1] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA
[2] Vanderbilt Univ, Div Clin Pharmacol, Nashville, TN USA
关键词
D O I
10.1097/00000542-200204000-00019
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. The efflux transporter P-glycoprotein, a member of the adenosine triphosphate-binding cassette superfamily, is a major determinant of the pharmacokinetics and pharmacodynamics of the opioid loperamide, a well-recognized antidiarrheal agent. Animal studies indicate that P-glycoprotein limits morphine entry into the brain. In this study, the authors examined whether other opioids of importance to anesthesiologists such as fentanyl, sufentanil, and alfentanil, and also morphine-6-glucuronide and morphine-3-glucuronide, are P-glycoprotein substrates and whether, in turn, these opioids act also as P-glycoprotein inhibitors. Methods: The transcellular movement of the various opioids, including loperamide and morphine, was assessed in L-MDR1 (expressing P-glycoprotein) and LLC-PK1 cell monolayers (P-glycoprotein expression absent). A preferential basal-to-apical versus apical-to-basal transport in the L-MDR cells but not the LLC-PK1 cells is seen for P-glycoprotein substrates. in addition, the effect of the various opioids on the transcellular movement of the prototypical P-glycoprotein substrate digoxin was examined in Caco-2 cell monolayers. IC50 values were calculated according to the Hill equation. Results: Loperamide was a substrate showing high dependence on P-glycoprotein in that basal-apical transport was nearly 10-fold greater than in the apical-basal direction In L-MDRI cells. Morphine also showed a basal-to-apical gradient in the L-MDR1 cell monolayer, indicating that it too is a P-glycoprotein substrate, but with less dependence than loperamide in that only 1.5-fold greater basal-apical directional transport was observed. Fentanyl, sufentanil, and alfentanil did not behave as P-glycoprotein substrates, whereas the morphine glucuronides did not cross the cell monolayers at all, whether P-glycoprotein was present or not. Loperamide, sufentanil, fentanyl, and alfentanil inhibited P-glycoprotein-mediated digoxin transport in Caco-2 cells with IC50 values of 2.5, 4.5, 6.5, and 112 muM, respectively. Morphine and its glucuronides (20 muM) did not inhibit digoxin (5 muM) transport in Caco-2 cells, and therefore IC50 values were not determined. Conclusions. Opioids have a wide spectrum of P-glycoprotein activity, acting as both substrates and inhibitors, which might contribute to their varying central nervous system-related effects.
引用
收藏
页码:913 / 920
页数:8
相关论文
共 35 条
[1]   Genetic dissection of the function of mammalian P-glycoproteins [J].
Borst, P ;
Schinkel, AH .
TRENDS IN GENETICS, 1997, 13 (06) :217-222
[2]  
Choo EF, 2001, CLIN PHARMACOL THER, V69, pP95
[3]  
CIRELLA VN, 1987, ANESTH ANALG, V66, P703
[4]   MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
CASALS, D ;
RITTMANGRAUER, L ;
BIEDLER, JL ;
MELAMED, MR ;
BERTINO, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) :695-698
[5]   Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine [J].
Drewe, J ;
Ball, HA ;
Beglinger, C ;
Peng, B ;
Kemmler, A ;
Schächinger, H ;
Haefeli, WE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (03) :237-246
[6]  
Edinboro LE, 1997, J FORENSIC SCI, V42, P741
[7]   SUFENTANIL DISPOSITION DURING CARDIOPULMONARY BYPASS [J].
FLEZZANI, P ;
ALVIS, MJ ;
JACOBS, JR ;
SCHILLING, MM ;
BAI, S ;
REVES, JG .
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1987, 34 (06) :566-569
[8]  
FORD JM, 1990, PHARMACOL REV, V42, P156
[9]   Genetic analysis of the multidrug transporter [J].
Gottesman, MM ;
Hrycyna, CA ;
Schoenlein, PV ;
Germann, UA ;
Pastan, I .
ANNUAL REVIEW OF GENETICS, 1995, 29 :607-649
[10]  
Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084